NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

基因檢測的全球市場□ COVID-19(2021-2025)的影響:按應用/技術

Genetic Testing. Global Market Forecasts for Applications and Technologies. Updated for COVID-19 Pandemic impact With Executive and Consultant Guides 2021 to 2025

出版商 Howe Sound Research 商品編碼 996942
出版日期 內容資訊 英文 453 Pages
商品交期: 最快1-2個工作天內
價格
基因檢測的全球市場□ COVID-19(2021-2025)的影響:按應用/技術 Genetic Testing. Global Market Forecasts for Applications and Technologies. Updated for COVID-19 Pandemic impact With Executive and Consultant Guides 2021 to 2025
出版日期: 2021年03月23日內容資訊: 英文 453 Pages
簡介

健康,疾病和遺傳之間的聯繫才被理解。隨著新的研究結果和更低的價格,基因檢測行業正顯示出創紀錄的增長。

本報告調查了全球基因檢測市場,定義並概述了市場,分析了對市場增長,主要趨勢,公司與公司之間的各種發展以及市場規模的變化和預測的各種影響因素。總結了使用情況,技術和地區,主要公司的概況等。

i。基因測試:戰略形勢分析-COVID-19的作用

ii。高管,市場營銷,銷售和業務開發人員指南

iii。管理顧問和投資顧問指南

第1章市場介紹/定義

  • 定義
  • 基因組學創新
  • 市場定義
  • 美國醫療市場/實驗室:前景

第2章市場概述

  • 進入業務運營商和角色
  • 基因檢測:類型/示例/討論
    • 植入前遺傳學診斷:新興市場
    • 產前診斷:新技術創造機會
    • 新生兒篩查
    • 診斷測試
    • 運營商檢查
    • 預測/症狀前測試
    • 藥理基因組學
    • 法醫檢查
    • 親子鑑定
    • 祖先檢查
  • 產業結構
  • 主要公司的市場份額

第3章市場趨勢

  • 增長增長因素
  • 生長抑製劑
  • 儀表/自動化
  • 診斷技術的發展

第4章最新動態

第5章主要公司簡介

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioM?rieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc. - A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd.
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

第6章世界市場規模:按國家

  • 市場預測/市場份額:按國家
  • 市場預測/市場份額:按用途
  • 市場預測/市場份額:按技術

第7章市場規模趨勢/預測:按用途

  • 新生兒檢查
  • NIPT
  • 預測性檢查
  • 腫瘤科檢查
  • DTC檢查
  • 其他

第8章市場規模趨勢/預測:按技術

  • PCR測試
  • NGS
  • 細胞遺傳學測試
  • 其他

第9章遺傳檢測的未來

附錄

目錄

OVERVIEW:

Is genomic cancer testing bouncing back? What has happened to Direct to Consumer testing? Will all newborns receive Whole Genomic Sequencing at birth?

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life, and new problems for the industry. The report forecasts the market size out to 2025. The report includes detailed breakouts for 14 countries and 5 regions.

Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Genetic Testing - Strategic Situation Analysis & Impact of COVID-19 Pandemic

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 Genetic Testing Definition in This Report
  • 1.2 The Genomics Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
    • 1.3.1 Newborn Screening
    • 1.3.2 Non Invasise Pregnancy Testing
    • 1.3.3 Predictive
    • 1.3.4 Oncology
    • 1.3.5 Direct to Consumer
    • 1.3.6 Other Application
    • 1.3.7 PCR
    • 1.3.4 NGS
    • 1.3.5 Cytogenetic
    • 1.3.6 Other Technology
  • 1.4 U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1 Market Participants Play Different Roles
    • 2.1.1 Supplier/pharmaceutical
    • 2.1.2 Independent lab specialized/esoteric
    • 2.1.3 Independent lab national/regional
    • 2.1.4 Independent lab analytical
    • 2.1.5 Public National/regional lab
    • 2.1.6 Hospital lab
    • 2.1.7 Physician lab
    • 2.1.8 DTC Lab
    • 2.1.9 Independent Genetic Testing Lab
    • 2.1.10 Audit Body
  • 2.2 Genetic Tests - Types, Examples and Discussion
    • 2.2.1 Preimplantation Genetic Diagnosis- An Emerging Market
    • 2.2.2 Prenatal Diagnosis - New Technologies Create Opportunity
    • 2.2.3 Newborn Screening
    • 2.2.2 Diagnostic Testing
    • 2.2.3 Carrier Testing
    • 2.2.6 Predictive and Presymptomatic Testing
    • 2.2.7 Pharmacogenomics
    • 2.2.8 Forensic Testing
    • 2.2.9 Parental Testing
    • 2.2.10 Ancestral Testing
  • 2.3 Industry Structure
    • 2.3.1 Hospital's Testing Share
    • 2.3.2 Economies of Scale
  • 2.3.2.1 Hospital vs. Central Lab
    • 2.3.3 Physician Office Lab's
    • 2.3.4 Physician's and POCT
  • 2.4 Market Shares of Key Genetics Players - Analysis

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Genetic Discoveries Creating New Diagnostic Markets
    • 3.1.2 Aging Population a Boon for Diagnostics
    • 3.1.3 Pharmacogenomics Drives Further Growth.
    • 3.1.4 Oncology and Liquid Biopsy Enter New Era
    • 3.1.5 Fertility Practice Growth drives market
    • 3.1.6 Direct to Consumer begins to break out
  • 3.2 Factors Limiting Growth
    • 3.2.1 Increased Competition Lowers Price
    • 3.2.2 Lower Costs
    • 3.2.3 Testing usage analysis curtailing growth.
    • 3.2.4 Wellness has a downside
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role.
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution
    • 3.4.2 Impact of NGS on pricing
    • 3.4.3 POCT/Self Testing Disruptive Force
    • 3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.5 CGES Testing, A Brave New World
    • 3.4.6 Biochips/Giant magneto resistance based assay

4. Genetic Testing Recent Developments

  • 4.1.1 Importance of This Section
  • 4.1.2 How to Use This Section
    • Progenity Revenues Fall on COVID-19 Effect
    • Natera Launches Tumor Genomic Profiling Assay
    • 23andMe To Go Public
    • Guardant Health to Offer Tumor Tissue Sequencing
    • Ancestry Quits Health Offering
    • DTC Firm MyDNA Merges With Gene by Gene
    • Aetna Coverage for NIPT to Include All Pregnancies
    • Agios Pharmaceuticals, PerkinElmer Partner on Hereditary Anemia Genetic Testing
    • Tumor, Germline Testing of Cancer Patients Can Give Discordant Results
    • Invitae Completes Acquisition of ArcherDx
    • Prenetics Receives $15M Investment
    • Sanford Health Invests $800K in TruGenomix as Part of PTSD Test Alliance
    • Preconception Carrier Screening Trial Begins in Australia
    • Genetic Testing Clinical Use Just Beginning
    • Fulgent Genetics Q1 Revenues Jump 44 Percent
    • Blueprint Genetics, NICER Consortium Developing Genetic Test for Immunologic,
    • Hematologic Disorders
    • Natera Terminates Qiagen Agreement for Developing NGS-Based Genetic Tests
    • Invitae Acquires Three Companies: YouScript, Genelex, Diploid
    • PerkinElmer SCID Test Chosen for Newborn Screening Evaluation in England
    • Germline Cancer Risk Mutations Sometimes Reported in Tumor Testing
    • Blueprint Genetics, Archimedlife to Launch Genetic Testing in North America
    • Invitae to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients
    • Phosphorus Offers DNA Testing to Assess Disease Risk
    • Arivale Shuts Down Personalized Wellness Business
    • ArcherDX Acquires Baby Genes
    • MDxHealth, LifeLabs Ink Distribution Agreement for Prostate Cancer Assay
    • Thermo Fisher Purchases 9 Percent Stake in Yourgene Health
    • Invitae Partners to Expand Free Epilepsy Genetic Testing Program
    • Illumina, Chinese Firm Partner on NGS System for Genetic Disease Dx
    • NanoString Technologies Prices $103.5M Common Stock Offering
    • Canine Consumer Genomics Firm Embark Veterinary Raises $10M
    • Yourgene Health to Acquire Elucigene
    • Helix, AdventHealth Partner on Genetic Screening Study

5. Profiles of Key Companies

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc. - A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd.
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

6. Global Market Size

  • 6.1 Global Market by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Country Market Shares
  • 6.2 Global Market by Application
    • 6.2.1 Table - Global Market by Application
    • 6.2.2 Chart - Application Share by Year
    • 6.2.3 Chart - Application Segment Growth Rates
    • 6.2.4 Chart - Application Segment Share Shifts
    • 6.2.5 Chart - Application Segment Share Base Year
    • 6.2.6 Chart - Application Segment Share Final Year
  • 6.3 Global Market by Technology
    • 6.3.1 Table - Global Market by Technology
    • 6.3.2 Chart - Technology Share by Year
    • 6.3.3 Chart - Technology Segment Growth Rates
    • 6.3.4 Chart - Technology Segment Share Shifts
    • 6.3.5 Chart - Technology Segment Share Base Year
    • 6.3.6 Chart - Technology Segment Share Final Year

7. Market Sizes by Application

  • 7.1 Newborn Testing Market
    • 7.1.1 Table Newborn - by Country
    • 7.1.2 Chart - Newborn Growth
  • 7.2 NIPT Market
    • 7.2.1 Table NIPT - by Country
    • 7.2.2 Chart - NIPT Growth
  • 7.3 Predictive Testing Market
    • 7.3.1 Table Predictive - by Country
    • 7.3.2 Chart - Predictive Growth
  • 7.4 Oncology Testing Market
    • 7.4.1 Table Oncology - by Country
    • 7.4.2 Chart - Oncology Growth
  • 7.5 DTC Testing Market
    • 7.5.1 Table DTC - by Country
    • 7.5.2 Chart - DTC Growth
  • 7.6 Other Testing Market
    • 7.6.1 Table Other - by Country
    • 7.6.2 Chart - Other Growth

8. Global Genetic Testing Market by Technology

  • 8.1 PCR Testing Market
    • 8.1.1 Table PCR - by Country
    • 8.1.2 Chart - PCR Growth
  • 8.2 NGS Market
    • 8.2.1 Table NGS - by Country
    • 8.2.2 Chart - NGS Growth
  • 8.3 Cytogenetic Testing Market
    • 8.3.1 Table Cytogenetic - by Country
    • 8.3.2 Cytogenetic - Predictive Growth
  • 8.4 Other Testing Market
    • 8.4.1 Table Other - by Country
    • 8.4.2 Chart - Other Growth

9. The Future of Genetic Testing

Appendices

  • I. United States Medicare System: 2021 laboratory Fees Schedule
  • II Methodology
    • II.1 Authors
    • II.2 Sources

Table of Tables

  • Table 1 Most Common Traditional Genetic Disorders
  • Table 2 Lab Spending 2014 to 2024
  • Table 3 Market Players by Type
  • Table 4 The Different Types of Genetic Tests
  • Table 5 Five Factors Driving Growth
  • Table 6 Four Factors Limiting Growth
  • Table 7 Key Diagnostic Laboratory Technology Trends
  • Table 8 Next Generation Sequencing Technologies - Speed and Cost
  • Table 9 Global Market by Country
  • Table 10 Global Market by Application
  • Table 11 Global Market by Technology
  • Table 12 Newborn Segment by Country
  • Table 13 NIPT Segment by Country
  • Table 14 Predictive Segment by Country
  • Table 15 Oncology Segment by Country
  • Table 16 DTC Segment by Country
  • Table 17 Other Segment by Country
  • Table 18 PCR Segment by Country
  • Table 19 NGS Segment by Country
  • Table 20 Cytogenetic Segment by Country
  • Table 21 Other Segment by Country
  • Table 22 2021 CLINICAL LAB FEE SCHEDULE

Table of Figures

  • Figure 1 Clinical Lab Spending 2014 to 2024
  • Figure 2 Top Ten Sequencing Companies
  • Figure 3 Percentage of World Population Over 65
  • Figure 4 Country Market Shares
  • Figure 5 Application Share by Year
  • Figure 6 Application Segment Growth Rates
  • Figure 7 Segment Share Shifts
  • Figure 8 Application Segment Share Base Year
  • Figure 9 Application Segment Share Final Year
  • Figure 10 Technology Share by Year
  • Figure 11 Technology Segment Growth Rates
  • Figure 12 Technology Segment Share Shifts
  • Figure 13 Technology Segment Share Base Year
  • Figure 14 Technology Segment Share Final Year
  • Figure 15 Newborn vs. Total Market Growth
  • Figure 16 NIPT vs. Total Market Growth
  • Figure 17 Predictive vs. Total Market Growth
  • Figure 18 Oncology vs. Total Market Growth
  • Figure 19 DTC vs. Total Market Growth
  • Figure 20 Other vs. Total Market Growth
  • Figure 21 PCR vs. Total Market Growth
  • Figure 22 NGS vs. Total Market Growth
  • Figure 23 Cytogenetic vs. Total Market Growth
  • Figure 24 Other vs. Total Market Growth